|
|
| (2 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Methyldopa#Warnings]] |
| {{Methyldopa}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==PRECAUTIONS==
| |
| | |
| ===General===
| |
| | |
| Methyldopa should be used with caution in patients with a history of previous liver disease or dysfunction (see “[[Methyldopa injection warnings|WARNINGS]]”).
| |
| Some patients taking methyldopa experience clinical edema or weight gain which may be controlled by use of a diuretic. Methyldopa should not be continued if edema progresses or signs of heart failure appear.
| |
| | |
| A paradoxical pressor response has been reported with intravenous administration of Methyldopate HCl Injection.
| |
| | |
| Hypertension has recurred occasionally after dialysis in patients given methyldopa because the drug is removed by this procedure.
| |
| | |
| Rarely involuntary choreoathetotic movements have been observed during therapy with methyldopa in patients with severe bilateral cerebrovascular disease. Should these movements occur, stop therapy.
| |
| | |
| ===Laboratory Tests===
| |
| | |
| [[Blood count]], [[Coombs test]], and liver function tests are recommended before initiating therapy and at periodic intervals (see “[[Methyldopa injection warnings|WARNINGS]]”).
| |
| | |
| ===Drug Interactions===
| |
| | |
| When methyldopa is used with other [[antihypertensive ]]drugs, potentiation of antihypertensive effect may occur. Patients should be followed carefully to detect side reactions or unusual manifestations of drug idiosyncrasy.
| |
| | |
| Patients may require reduced doses of anesthetics when on methyldopa. If [[hypotension ]]does occur during anesthesia, it usually can be controlled by [[vasopressors]]. The adrenergic receptors remain sensitive during treatment with methyldopa.
| |
| | |
| When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. Read the circular for lithium preparations.
| |
| | |
| [[Monoamine oxidase]] ([[MAO]]) inhibitors: See [[Methyldopa injection contraindications|CONTRAINDICATIONS]].
| |
| | |
| ===Drug/Laboratory Test Interactions===
| |
| | |
| Methyldopa may interfere with measurement of: urinary uric acid by the phosphotungstate method, serum [[creatinine ]]by the alkaline picrate method, and [[SGOT ]]by colorimetric methods. Interference with spectrophotometric methods for SGOT analysis has not been reported.
| |
| | |
| Since methyldopa causes fluorescence in urine samples at the same wavelengths as [[catecholamines]], falsely high levels of urinary catecholamines may be reported. This will interfere with the diagnosis of [[pheochromocytoma]]. It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery. Methyldopa does not interfere with measurement of [[VMA ]]([[vanillylmandelic acid]]), a test for pheochromocytoma, by those methods which convert [[VMA ]]to vanillin. Methyldopa is not recommended for the treatment of patients with pheochromocytoma. Rarely, when urine is exposed to air after voiding, it may darken because of breakdown of methyldopa or its metabolites.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METHYLDOPATE HYDROCHLORIDE INJECTION, SOLUTION [AMERICAN REGENT, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5f25053-a9f3-48b9-a412-078f5ee942fd | publisher = | date = | accessdate = 10 March 2014 }}</ref>
| |
| | |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |